A buried provision in Alaska's HB195 gives independent pharmacies new prescribing authority—and it could affect how your company manages employee health benefits and supplier relationships.
Most Alaska manufacturing owners don't realize that a healthcare bill passed in 2024 contains a provision that directly expands what independent pharmacies can do—and bill for. Understanding HB195's pharmacy language matters if you're managing employee benefits, supply chains, or relationships with local healthcare providers.
Section 33 of HB195 amended Alaska Statute 08.80.337(a) to allow pharmacists to enter into collaborative practice agreements with physicians or other healthcare providers. Under these agreements, pharmacists can now prescribe and administer drugs and devices without requiring separate government approval or paying additional fees.
The key word here is "collaborative." A pharmacist doesn't operate independently; they work under a written agreement with a licensed physician or other qualified provider. But once that agreement is in place, the pharmacist gains prescribing and administering authority—effectively expanding their scope of practice from dispensing medications to actively managing patient treatment.
If your company operates in Alaska, this affects you in several concrete ways:
Employee Health Benefits: Your workers may now access more services at local independent pharmacies without leaving town or waiting for a doctor's appointment. For rural manufacturing operations, this can reduce employee downtime and improve access to care.
Supplier Relationships: If you work with healthcare providers or pharmacies as part of your supply chain or community partnerships, you're dealing with a provider landscape that just expanded its service offerings.
Local Healthcare Infrastructure: Independent pharmacies—often small businesses themselves—can now offer expanded services, which strengthens local healthcare capacity. This can matter for workforce retention and community stability in areas where manufacturing clusters exist.
The provision becomes effective January 1, 2027, per Section 87 of HB195. This gives pharmacies and physicians time to develop and execute collaborative practice agreements before the authority kicks in. If you're evaluating your company's healthcare strategy or benefits structure, 2027 is the year this change becomes operational.
This is important: pharmacists operate within the collaborative agreement. They're not independent prescribers. The agreement must specify which drugs, devices, and patient populations fall under the pharmacist's authority. The supervising physician retains oversight. This is narrower than what pharmacists can do in some other states, but it's a meaningful expansion from Alaska's previous rules.
The provision doesn't require government approval or fees for the collaborative agreement itself—meaning small independent pharmacies can implement this without additional regulatory burden or cost, making it more accessible for smaller operations.
If you manage employee health benefits or work closely with local healthcare providers, it's worth understanding how this affects your options starting in 2027. The Alaska Pharmacists Association and your industry trade group may have more detailed guidance as the effective date approaches.
For a free, detailed breakdown of how HB195 affects Alaska manufacturing specifically, contact your local trade association.